Comparison of treatment duration for drug resistant pulmonary tuberculosis with vs. without type 2 diabetes mellitus

Abstract

Background: Pulmonary TB and DM are a combination of high medical-epidemiological conflict and high global impact because they are interdependent. Pulmonary TB cannot improve in the presence of unmanaged diabetes. Pulmonary TB in people with DM has particular characteristics, so if it is not diagnosed and treated, it is difficult to understand the effects of TB drugs and oral antidiabetic drugs. The purpose of this study was to compare the length of treatment for drug-resistant pulmonary TB in the presence vs. the absence of type 2 DM Methods: This study used a cross-sectional with a single population proportion method. The research subjects were enrolled using the consecutive sampling technique. The comparison was between drug-resistant TB patients with and without type 2 DM. The total sample was initially recruited was 80 patients, and after applying the inclusion and exclusion criteria, 22 study subjects remained. Results: The 80 samples studied were 44 drug-resistant pulmonary TB patients with type 2 DM and 36 patients without type 2 DM. The male:female ratio was 53 (66.3%) to 27 (33.8%). GeneXpert results in both groups indicated rifampicin resistance. In the comparison of length of treatment, drug-resistant pulmonary TB patients with type 2 DM who stayed on their treatment until recovery most often recovered in the 18th to 24th months, totalling 13 people, whereas the drug-resistant pulmonary TB patients without type 2 DM who stayed on their treatment until recovery recovered in the 6th to 24th months, totalling 9 people (Mann‒Whitney test P = 0.000). Conclusions:The treatment period for drug-resistant pulmonary tuberculosis patients with type 2 DM is much longer than that for drug-resistant pulmonary tuberculosis patients without type 2 DM.